<DOC>
	<DOCNO>NCT00409097</DOCNO>
	<brief_summary>The purpose study determine whether Rosiglitazone , decrease ADMA concentration thereby increase arginine/ADMA ratio critically ill patient .</brief_summary>
	<brief_title>Effect Rosiglitazone ADMA Critical Illness</brief_title>
	<detailed_description>Endothelial vasodilatation dysfunction precedes development arteriosclerosis . The endothelium play pivotal role control vascular tone release nitric oxide ( NO ) . The amino acid arginine sole substrate enzyme NO synthase ( NOS ) . Asymmetric dimethylarginine ( ADMA ) endogenous derivative arginine inhibits NOS . Thus arginine/ADMA ratio important determinant NO production NOS . ADMA independent risk factor cardiovascular disease , elevate level ADMA also show strong independent predictor ICU mortality . The central mechanism ADMA may cause deterioration critically ill patient impair organ blood flow reduce cardiac function , especially stress . Accumulation ADMA could thereby causative factor development multi organ failure ( MOF ) . Thus inhibition NO production ADMA may become especially important cardiac demand increase .</detailed_description>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Multiple Organ Failure</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>critically ill patient age 18 75 year SOFA score &gt; 7 history Diabetes mellitus history hypercholesterolemia history hyperhomocysteinemia impair hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>ADMA</keyword>
	<keyword>MOF</keyword>
	<keyword>Critical illness</keyword>
</DOC>